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Type D personality and diabetes predict the onset of
depressive symptoms in patients after percutaneous
coronary intervention
Susanne S. Pedersen, PhD,a,b Andrew T.L. Ong, MBBS, FRACP,a Karel Sonnenschein, MSc,a
Patrick W. Serruys, MD, PhD, FESC, FACC,a Ruud A.M. Erdman, PhD,a,c and Ron T. van Domburg, PhDa
Rotterdam and Tilburg, The NetherlandsBackground Depression is common in cardiac patients and has been associated with adverse clinical outcome.
However, little is known about predictors of the onset of depressive symptoms. We examined predictors of the onset of
depressive symptoms at 12 months post–percutaneous coronary intervention (PCI) in patients treated in the drug-eluting
stent era.
Methods Unselected patients, free from depressive symptoms at 6 months with a depression score at 12 months treated
with PCI with either drug-eluting or bare stent implantation as part of the RESEARCH registry qualified for inclusion in the
current study. Patients completed the Hospital Anxiety and Depression Scale at 6 and 12 months and the Type D Personality
Scale (DS14) at 6 months post-PCI. Six months was used as the baseline assessment.
Results Of 542 patients, 41 (8%) had developed significant depressive symptoms at 12 months. The occurrence of a
new cardiac event between 6 and 12 months post-index event did not influence the incidence of depressive symptoms at
12 months. Depressive patients were more likely to have a type D personality (34% vs 16%, P = .003) and diabetes (24% vs
11%, P = .01) than nondepressive patients. Type D personality (odds ratio 3.04, 95% CI 1.50-6.16) and diabetes (odds
ratio 2.75, 95% CI 1.25-6.05) were independent predictors of the onset of depressive symptoms 12 months post-PCI in
adjusted analyses. In patients with neither risk factors (type D or diabetes), the incidence of depression was 5.1% with the
incidence more than doubling to 13.2% and 30% for each additional risk factor.
Conclusions Type D personality and diabetes comprise risk factors for the onset of depressive symptoms post-PCI. In
clinical practice, patients with these risk factors should be identified and considered for psychosocial intervention targeting
depression to enhance secondary prevention. (Am Heart J 2006;151:367.e12367.e6.)Depression has gained status as an important risk
factor for morbidity and mortality in patients with
established cardiovascular disease (CVD). Depression is
prevalent in approximately 20% to 30% of cardiac
patients and has been shown to confer a 2-fold increased
risk of adverse clinical outcome adjusting for established
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doi:10.1016/j.ahj.2005.08.012meta-analyses.4,5 Depression has also been related to
nonadherence to medical treatment recommenda-
tions,6,7 impaired health status,8,9 increased risk of
rehospitalization,10,11 and may also be associated with
increased health care consumption although results to
date have been mixed.12,13
The recent Enhancing Recovery in Coronary Heart
Disease (ENRICHD) study and the Sertraline Antide-
pressant Heart Attack Randomized Trial (SADHART)
showed that psychosocial intervention and treatment
with selective serotonin re-uptake inhibitors successfully
reduce depressive symptoms14,15 and improve health
status.16 However, a reduction in depressive symptoms
did not lead to a concomitant risk reduction in clinical
adverse events.14,15 Hence, we are still at large as to
which intervention is effective in reducing depressive
symptoms while simultaneously leading to improved
prognosis in patients with established CVD.
The key to optimizing risk stratification and second-
ary prevention in clinical practice may lie in the
Figure 1
Flowchart of patient selection.
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367.e2identification of factors that predict the onset of
depressive symptoms. Lack of social support, hostility,
depressive symptoms during hospitalization, exhaustion
before myocardial infarction (MI), younger age, smoking,
self-reported previous cardiac condition, self-reported
history of anxiety and depression, social factors, and
impaired health status have all been associated with the
development of depressive symptoms, whereas denial
has been shown to be protective.17-20
However, a paucity of studies have examined the
influence of personality factors on the development of
depressive symptoms in cardiac patients, and no study
has examined predictors of the onset of depressive symp-
toms in unselected patients treated with percutaneous
coronary intervention (PCI) in the drug-eluting stent era.
The distressed (type D) personality is an emerging risk
factor that has been associated with increased psycho-
logical distress, symptoms of exhaustion, adverse health
status, and adverse clinical outcome despite appropriate
treatment.21-24 Type D is a risk factor on par with
established biomedical risk factors with type D patients
being above a 4-fold increased risk of adverse clinical
outcome.21,22 This personality taxonomy is defined as
the tendency to experience increased negative emotions
paired with the nonexpression of these emotions in
social interactions. Although type D is often mistaken for
depression, it is more than negative affect because it also
includes how patients deal with this affect.25 Because
type D personality has been shown to predict depressive
affect at 5 years’ follow-up in a mixed group of cardiac
patients in the pre–drug-eluting stent era, 21 type D may
also be a determinant of the onset of depressive
symptoms in post-PCI patients treated in the drug-
eluting stent era.
The aim of the current study was to determine
predictors of the onset of depressive symptoms at
12 months post-PCI in patients treated in the drug-
eluting stent era who were not depressed at 6 months.
Methods
Study design and participants
Of 875 (71%) unselected patients participating in a psycho-
logical substudy of the RESEARCH registry, patients (n = 542)
who were free from depressive symptoms at 6 months and had
a depression score at 12 months qualified for inclusion in the
current study. A flowchart of the patient selection for the
current study is shown in Figure 1. Details of the RESEARCH
study design26 and the psychological substudy have been
published elsewhere.22 In brief, the registry was set up to
evaluate the efficacy of the sirolimus-eluting stent. For this
purpose, no clinical or anatomical exclusion criteria were
applied so as to reflect patients seen in daily clinical practice.
Of note, 68% of the patients included in the RESEARCH registry
would not have qualified for inclusion in clinical trials.27
Surviving patients at 6 and 12 months post-PCI were asked to
complete the Hospital Anxiety and Depression Scale (HADS)
and the Type D Personality Scale. Questionnaires wereadministered at 6 months post-PCI in order for patients to be in
a stable medical condition and to avoid measuring psycholog-
ical distress related to the procedure; a similar approach has
been adopted by others.28,29 Type D is a stable personality
construct25 rendering the time point for assessment of the
construct of less importance. Clinical variables were also
obtained at 6 months.
The study was approved by the local medical ethics
committee and conducted in accordance with the Declaration
of Helsinki. Every patient provided written informed consent.
Materials
Sociodemographic and clinical variables. Sociodemo-
graphic variables included sex and age. Clinical variables
included prior MI, prior PCI, prior coronary artery bypass graft
(CABG) surgery, recent cardiac event (defined as MI, PCI, or
CABG between 6 and 12 months post-PCI), sirolimus-eluting or
bare metal stent implantation, multivessel disease, diabetes
mellitus (defined as receiving oral hypoglycemic agents or
insulin), dyslipidemia (indicated by total cholesterol levels
N240 mg/dL or on lipid-lowering medication), hypertension
(defined as being on antihypertensive therapy), renal impair-
ment (indicated by creatinine clearance V60 mL/min), and
smoking status (assessed by means of self-report).
Depressive symptoms. The 7-item depression subscale of
the HADS was used to evaluate depressive symptoms.30 The
items are answered on a 4-point Likert scale from 0 to 3 (score
range 0-21). We used a cutoff score z8 to quantify patients
with depressive symptoms, as this cutoff yields an optimal
balance between sensitivity and specificity.31 The HADS is a
valid and reliable instrument31 and has been shown to predict
mortality in patients referred for exercise testing.32 The HADS
was administered at 6 and 12 months post-PCI.




(n = 501) OR 95% CI P
Demographics
Males (%) 63 75 0.58 0.30-1.13 .11
Age, mean (SD) 64 (12) 62 (10) 1.02 0.99-1.05 .19
Personality
Type D (%) 34 16 2.81 1.41-5.60 .003y
Clinical variables
Sirolimus-eluting stent (%) 37 42 0.80 0.41-1.55 .51
Prior cardiac eventz 59 51 1.37 0.72-.2.62 .34
Multivessel disease (%) 59 50 1.44 0.76-2.75 .27
Diabetes mellitus§ (%) 24 11 2.67 1.24-5.75 .01t
Dyslipidemiab (%) 73 81 0.65 0.31-1.34 .24
Hypertension# (%) 44 36 1.37 0.72-2.61 .34
Renal impairment44 (%) 39 30 1.53 0.79-2.95 .20
Current smokingyy (%) 39 30 1.47 0.76-2.83 .25
Medication
h-Blockers (%) 95 99 0.28 0.06-1.38 .12
Calcium antagonists (%) 56 46 1.49 0.79-2.84 .22
Nitrates (%) 10 9 1.12 0.38-3.30 .83
ACE inhibitors (%) 22 25 0.85 0.39-1.82 .67
Statins (%) 61 69 0.69 0.36-1.34 .27
4A cutoff z8 on the HADS was used to denote those with depressive symptoms.
yP b .01.
zMI, CABG, or PCI before the index PCI.
§Receiving oral hypoglycemic agents or insulin.
tP b .05.
bTotal cholesterol levels N240 mg/dL or on lipid-lowering medication.
#Being on antihypertensive therapy.
44Indicated by creatinine clearance V60 mL/min.
yyBased on self-report.
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(DS14) was used to assess type D personality.25 Items are
answered on a 5-point Likert scale from 0 to 4 with a score range
of 0 to 28 for each subscale. The scale consists of two subscales:
negative affectivity (eg, bI often feel unhappyQ) and social
inhibition (eg, bI am a dclosedT personQ); patients who score high
on both components—as determined by a standardized cutoff
z10—are categorized as type D. The psychometric properties of
the DS14 are good with Cronbach a = .88/.86 for the negative
affectivity and social inhibition subscales, respectively.25 Type D
is a stable personality construct, as indicated by a test-retest
reliability over a 3-month period (r = 0.72/0.82 for the negative
affectivity and social inhibition subscales, respectively) and
because it has been shown to be independent of mood and
health status.25 The DS14 was administered 6 months post-PCI.
Statistical analyses
Discrete variables were compared with the m2 (Fisher exact
test when appropriate) and are presented as percentages.
Continuous variables were compared with the Student t test
and are presented as mean F SD. Univariable and multivariable
logistic regression analyses were performed to delineate
predictors of the development of depressive symptoms
12 months post-PCI. The multivariable analyses were performed
in two steps due to the relatively small number of patients with
depressive symptoms. In the first step, we entered type D
personality, sex, age, stent type, prior cardiac event, multi-
vessel disease, diabetes, dyslipidemia, hypertension, renal
impairment, and smoking in a multivariable model with abackward selection using a liberal P value criterion (entry
criteria P = .05 and removal criteria P = .50). This procedure is
considered one of the least harmful of the stepwise proce-
dures, given that a liberal P value criterion compensates by
making more likely that truly important predictors will be
retained in the model.33 In the second step, all significant
variables from the first analysis were included using an enter
procedure adding sex, age, multivessel disease, and stent type
(sirolimus-eluting or bare metal stent) irrespective of whether
the latter covariates were significant in the first model. We
chose to adjust for these covariates, as sex and age are included
standardly in multivariable models in psychosomatic research
and have been associated with depressive symptoms; multi-
vessel disease was included to adjust for disease severity, ruling
out the possibility that onset of depressive symptoms could be
due to more severe cardiac disease; stent type was included as
there is as yet no knowledge of the impact of drug-eluting
stents on psychological outcome. All tests were 2-tailed. A
P value b.05 was considered to be statistically significant. Odds
ratios (ORs) with 95% CIs are reported. All statistical analyses
were performed using SPSS 12.0.1 for Windows.Results
Patient characteristics stratified by
depressive symptoms
Of the 542 patients who were not depressed at
6 months, 41 (8%) developed significant depressive
Table II. Independent predictors of depressive symptoms
12 months post-PCI (multivariable analysis)
Variable OR 95% CI P
Type D personality 3.04 1.50-6.16 .0024
Diabetes mellitusy 2.75 1.25-6.05 .012z
Male sex 0.62 0.31-1.24 .18
Age 1.02 0.99-1.05 .25
Multivessel disease 1.34 0.69-2.63 .39
Sirolimus-eluting stent 0.72 0.37-1.43 .35
4P b .01.
yReceiving oral hypoglycemic agents or insulin.
zP b .05.
Figure 2
Incidence of depressive symptoms at 12 months stratified by number
of risk factors* (*type D personality and diabetes).
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367.e4symptoms at 12 months. Characteristics at 6 months
comparing those who developed depressive symptoms
at 12 months versus those who did not are presented in
Table I (columns 1 and 2). Depressed patients were
more likely to have a type D personality (34% vs 16%, P =
.003) and diabetes (24% vs 11%, P = .01) than
nondepressed patients. No other statistically significant
differences were found between the two groups
on characteristics at 6 months, including on
cardiac medication.
We also examined whether the occurrence of a new
cardiac event (defined as MI, CABG, or PCI) between
6 and 12 months post-index event influenced the
incidence of depressive symptoms. However, depressed
patients were not more likely to have had a recent event
between 6 and 12 months compared with nondepressed
patients (7.3% vs 5.2%, P = .47).
Predictors of depressive symptoms
Type D personality and diabetes were predictors of
the onset of depressive symptoms 12 months post-PCI in
univariable analyses (Table I, columns 3-5). No demo-
graphic or other clinical risk factors were associated
with the onset of depressive symptoms.
In a stepwise model using a backward selection with a
liberal P value for removal (P = .50), we entered all
baseline characteristics listed in Table I except for
cardiac medication. Type D personality (OR 3.29, 95% CI
1.60-6.80, P = .01) and diabetes (OR 2.76, 95% CI 1.25-
6.10, P = .12) were the only significant predictors of the
onset of depressive symptoms. In a subsequent multi-
variable analysis using the enter procedure, type D
personality and diabetes remained independent predic-
tors of depressive symptoms 12 months post-PCI
adjusting for sex, age, multivessel disease, and stent type
(Table II). The risk associated with type D (OR 3.04, 95%
CI 1.50-6.16) and diabetes (OR 2.75, 95% CI 1.25-6.05)
was of a similar magnitude.
In patients with neither risk factors (type D or
diabetes), the incidence of depression was 5.1% with the
incidence more than doubling to 13.2% and 30% foreach additional risk factor, showing a graded relation-
ship (Figure 2). Although the incidence in depressive
symptoms did not differ significantly for patients with
one versus both risk factors ( P = .145), this is likely due
to reduced statistical power given that only 10 patients
had two risk factors.
Discussion
This is the first study to examine predictors of the
onset of depressive symptoms in unselected post-PCI
patients in general and in the drug-eluting stent era in
particular. Type D personality and diabetes were both
associated with close to a 3-fold increased risk of
developing depressive symptoms 12 months post-PCI.
Personality factors are known to increase the risk of
developing depressive symptoms in the general popu-
lation.34,35 As such, personality may be construed as a
vulnerability factor. Type D personality has previously
been identified as an important explanatory factor of
individual differences in distress23,24 and clinical out-
come in patients with established CVD.21,22 In the
current study, we found that type D also comprises a
risk factor for the onset of depressive symptoms in
unselected patients post-PCI. This supports the notion
that personality comprises a vulnerability factor for the
onset of depressive symptoms not only in the general
population but also in patients with established CVD.
Diabetes was also an independent risk factor for the
development of depressive symptoms on par with the
risk associated with type D. We found no relationship
between disease severity and the development of
American Heart Journal
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367.e5depressive symptoms at 12 months, which is consistent
with the results of previous studies.17,20
Similar to Havranek et al,20 we found a graded rela-
tionship between depressive symptoms and risk factors
with the incidence of depression increasing to N2-fold
with the addition of each risk factor (ie, type D and
diabetes). Psychosocial risk factors are known to cluster
together within individuals36 and also to act in synergy
with traditional biomedical CVD risk factors in producing
adverse clinical outcome.37 In a population-based study,
patients with concomitant diabetes and CVD who were
depressed were almost two times more likely to have
three or more known CVD risk factors compared with
the nondepressed.38 Using poor clinical outcome and
health care costs as end points, type D has also been
shown to act in synergy with age and left ventricular
dysfunction in the pre–drug-eluting stent era.21
This study has some limitations. First, we used a self-
report measure rather than a diagnostic interview to
assess depression. However, the HADS, which was the
measure used in the current study, has good sensitivity
and specificity indicating that it is a reasonable predictor
of a clinical diagnosis of depression.31 Although we also
had no information about history of depression, patients
only qualified for inclusion in this substudy if they were
not depressed at 6 months. In other words, patients who
developed depressive symptoms at 12 months were
incident cases. Second, the number of depressed
patients was relatively small, limiting the number of
covariates that we could adjust for in multivariable
analyses. Although some steps were undertaken to limit
overfitting in the regression model, we cannot rule out
that overfitting may have influenced our results. Third,
17% (111/653) of the patients with no depression at
6 months were excluded because they had dropped out
during follow-up. Fourth, we had no information on
treatment for depressive symptoms. Finally, depressive
symptoms and type D personality were evaluated at
6 months rather than at the time of the index PCI. This
time point was chosen to ensure that patients were in a
stable medical condition and that psychological symp-
toms did not reflect symptoms related to the index
procedure. However, the 6-month time gap may have
been unnecessarily wide given that assessment at
1 month postprocedure has been shown to comprise a
sufficient time frame.28 The time point for assessing type
D personality is of less importance given that it is a
stable personality construct.25
Nevertheless, a strength of the current study is that it
consisted of unselected patients, as no patients were
excluded due to clinical or anatomical criteria. Hence,
the patients represent those seen in daily clinical
practice. In addition, this study points to two poten-
tially important risk factors for the onset of depressive
symptoms, namely, type D personality and diabetes. If
these findings can be confirmed in future studies, itmay be important to screen for type D personality and
diabetes, as these patients should be considered for
psychosocial intervention to prevent the development
of depressive symptoms. This would also lead to
efficient and cost-effective allocation of health care
resources, as most patients (73%) in the current study
had neither of the risk factors. Moreover, the presence
of CVD and depression has been associated with
significantly increased health care costs in patients with
diabetes39 and depression13 and the convergence of
type D, sex, and left ventricular dysfunction with
increased health care costs in patients with CVD.21
Hence, screening may not only lead to gains for
patients in terms of increased survival, less psycholog-
ical distress, and improved health-related quality of life,
but there may also be gains to society in terms of
reduced health care costs. Taken together, these results
indicate that the use of algorithms, as suggested by
Rozanski et al36 already in 1999, that also include
psychosocial risk factors may improve risk stratification
in clinical practice.
In conclusion, this preliminary study showed that type
D personality and diabetes predict the onset of depres-
sive symptoms 12 months post-PCI in unselected
patients. We found a graded relationship between
depressive symptoms and the risk factors type D and
diabetes, with the incidence of depressive symptoms
increasing in an almost exponential fashion with the
addition of each risk factor. Additional studies are
warranted to confirm these findings, as knowledge of
risk factors for depression onset may point to targets for
psychosocial intervention.References
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